Twist Bioscience Corp (TWST)
Twist Bioscience Corp (TWST) from its SEC filings: 2025 revenue $376.6 million (+20% vs the year before), net margin -21%, free cash flow -$75.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $376.6 million |
| Revenue growth | +20% |
| Net income | -$77.7 million |
| Net margin | -20.6% |
| Free cash flow | -$75.6 million |
| Diluted EPS | $-1.30 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +23% |
| Cash | $117.4 million |
| Long-term debt | $625,000 |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.